Mountain Valley MD (MVMD) AI Stock Analysis

• Market Cap: C$7.05M
• Dividend Yield: N/A
• Average Volume (3M): 205.59K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.09
• Revenue Growth: -46.59%
• EPS Growth: 8.26%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 352,354,950
• 10 Day Avg. Volume: 152,980
• 30 Day Avg. Volume: 205,595
• PEG Ratio: 0.14
• Price to Book (P/B): 3.44
• Price to Sales (P/S): 177.77
• P/FCF Ratio: -2.23
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: C$0.02 ▲(0.00% Upside)
• Action: Reiterated Date: 03/17/26
• Date: Action: Reiterated 03/17/26

The score is held down primarily by weak financial performance (minimal/declining revenue, large losses, and persistent cash burn with a shrinking equity cushion). Technicals provide some offset with a mild upward trend versus moving averages and generally neutral RSI, but valuation support is limited due to negative earnings and no dividend.

Positive Factors

Low leverage

Near-zero reported debt materially reduces liquidity stress and bankruptcy risk, giving management structural flexibility to pursue R&D, partnerships or occasional financing without high fixed interest burdens. This durable low-leverage profile supports survival during extended cash burn periods.

Improving gross margin signal

A return to positive gross profit indicates the core product or cost base can generate margin once volume or pricing improves. If sustained, positive gross margins create a pathway to operational leverage: revenue growth would flow more directly to operating profit as fixed costs are absorbed.

Industry positioning

Operating in specialty and generic pharmaceuticals provides structural demand, regulatory barriers, and niche pricing power versus commodity sectors. These industry features create longer-term commercial opportunities for differentiated formulations or contracts with payors and could support durable revenue streams if development/approval succeeds.

Negative Factors

Persistent cash burn

Consistent negative operating and free cash flow forces repeated external funding, diluting shareholders and distracting management. Over a multi-quarter horizon, persistent burn limits runway for clinical or commercial programs, constrains strategic optionality, and elevates financing and execution risk.

Eroded equity cushion

A steep decline in shareholders' equity weakens the company’s capital buffer to absorb further losses and increases the chance of distress in adverse scenarios. A thin equity base also reduces borrowing capacity and makes future financing more dilutive or costly, impairing long-term stability.

Minimal, volatile revenue and deep losses

Very small and falling revenue alongside substantial net losses shows the business has not yet achieved commercial traction. Structural scalability is unclear: without consistent revenue growth, operating leverage cannot be realized and continued losses will likely require dilutive financing or cost cuts that impair long-term value creation.

Mountain Valley MD Business Overview & Revenue Model

Company Description

Mountain Valley MD Holdings Inc., through its subsidiary, Mountain Valley MD Inc., operates as a health and wellness company. The company engages in the implementation and licensing of its technologies to pharmaceutical, vaccine, and nutraceutical third parties. It offers Quicksome oral drug formulation and delivery technologies; Quicksol solubility formulation technology; and dose sparing adjuvant. In addition, the company is developing IM032 for the treatment of male beagle dogs for comparing intramuscular and subcutaneous dosing. Mountain Valley MD Holdings Inc. is headquartered in Concord, Canada.

How the Company Makes Money

null

Mountain Valley MD Financial Statement Overview

Summary

Overall financials are weak: revenue is very small and down sharply year over year, the company is deeply loss-making, and operating/free cash flow remain consistently negative (ongoing cash burn). Low/near-zero debt is a meaningful positive, but the equity base has eroded substantially, increasing financing and dilution risk.

Income Statement

Revenue remains very small and volatile, with 2025 annual revenue down ~85% year over year (C$49k vs. C$60k). Profitability is materially weak: the company is deeply loss-making with negative operating profit and a net loss of ~C$7.5M in 2025, translating to extremely negative net margins. A positive point is that 2025 gross profit is positive (unlike 2024), but overall the income statement profile reflects an early-stage business with heavy operating spend relative to revenue and no clear earnings traction yet.

Balance Sheet

Leverage is a clear strength: reported total debt is effectively zero in 2024–2025 and very low historically, which reduces financial risk. However, the balance sheet has weakened meaningfully as equity declined from ~C$30.5M (2021) to ~C$2.5M (2025), consistent with ongoing losses eroding the capital base; returns on equity are strongly negative. Overall, low debt helps, but the shrinking equity cushion is a key concern.

Cash Flow

Cash generation is weak, with operating cash flow negative every year shown and worsening to about -C$3.9M in 2025. Free cash flow is also consistently negative (about -C$3.9M in 2025), indicating ongoing cash burn and continued reliance on external funding over time. While cash burn did not spike dramatically versus 2024, the persistent negative cash profile and lack of self-funding capacity are the central risks.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	31.00K	49.00K	60.00K	0.00	110.00K	0.00
Gross Profit	18.00K	49.00K	-346.00K	-446.00K	70.00K	-430.19K
EBITDA	-1.22M	-3.16M	-2.78M	-6.89M	-9.29M	-4.77M
Net Income	-5.96M	-7.47M	-7.67M	-7.44M	-9.71M	-8.14M
Balance Sheet
Total Assets	594.00K	2.74M	8.97M	16.77M	25.27M	31.61M
Cash, Cash Equivalents and Short-Term Investments	316.00K	1.72M	5.92M	9.71M	14.22M	19.51M
Total Debt	89.00K	0.00	0.00	6.00K	44.00K	84.00K
Total Liabilities	130.00K	209.00K	258.00K	591.00K	422.00K	1.11M
Stockholders Equity	464.00K	2.53M	8.71M	16.18M	24.85M	30.50M
Cash Flow
Free Cash Flow	-1.07M	-3.91M	-3.80M	-4.85M	-5.68M	-4.31M
Operating Cash Flow	-1.07M	-3.90M	-3.30M	-4.79M	-5.59M	-3.86M
Investing Cash Flow	187.00K	-290.00K	-503.00K	1.89M	-98.00K	-149.00K
Financing Cash Flow	89.00K	0.00	-6.00K	-1.60M	395.00K	21.78M

Mountain Valley MD Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MVMD, the sentiment is Positive. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and above the 200-day MA of 0.02, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 52.83 is Neutral, neither overbought nor oversold. The STOCH value of 77.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:MVMD.

Mountain Valley MD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
MVMD	46 Neutral	C$7.05M	-1.56	-461.32%	―	-46.59%	8.26%
RVV	46 Neutral	C$29.30M	-4.56	899.59%	―	―	-80.42%
LOBE	46 Neutral	C$18.86M	-2.55	―	―	-100.00%	-8.70%
PCLO	44 Neutral	C$9.69M	5.19	―	―	15.64%	58.47%
AYUR	40 Underperform	C$1.95M	-1.54	-271.33%	―	15.95%	-1.81%
CANB	40 Underperform	C$2.77M	-10.76	-11.42%	―	-5.87%	-239.53%

Mountain Valley MD Corporate Events

Mountain Valley MD Details Year-End Commercialization Gains Across Core Platforms

Mountain Valley MD issued a year-end update highlighting commercialization progress across its three main platforms, with management emphasizing disciplined execution in product development, field validation and commercial foundations as the business enters a new growth phase. In nutraceuticals, the company is scaling its Quicksome™ technology through an exclusive U.S.-based GMP manufacturing partner, supporting ongoing production for Circadian Wellness’s Quicksome™-based Eons sublingual products and advancing new licensing opportunities in areas such as menopause symptom relief, muscle recovery, anti-inflammation and joint health, while preparing a fenugreek glycosides testosterone product launch via a licensee in the first half of 2026 and positioning its “Mountains Of…” branded line for either direct or white-label distribution; in agriculture, MVMD continues to validate and commercialize its Agrarius technology across diverse crops and regions, reinforcing its potential role in sustainable farming and laying a data-driven foundation for longer-term adoption.

The most recent analyst rating on (TSE:MVMD) stock is a Hold with a C$0.02 price target. To see the full list of analyst forecasts on Mountain Valley MD stock, see the TSE:MVMD Stock Forecast page.